Strategies to eradicate antibiotic-resistant Mycobacterium tuberculosis (MTB) Project

Recently, Adlego Biomedical successfully performed a highly demanding 4-month long project at a Biosafety Level 3 laboratory in accordance to our ethical approval by the Swedish Board of Agriculture (Jordbruksverket). As a proud partner of a Vinnova-funded project together with Karolinska Institutet (Sweden) and Birla Institute of Technology and Science (India), this project aimed to develop strategies to eradicate antibiotic-resistant Mycobacterium tuberculosis (MTB). One month after aerosol infection with live MTB, mice were treated for 2 months and then sacrificed to harvest organs for a colony-forming assay. The treatment involved thrice-daily intravenous (i.v.) injections of the test item, Compound X, and once daily per-oral (p.o.) administration of isoniazid, which served as a positive control compound. In total, more than 2380 i.v. injections and 800 p.o. administrations were successfully executed. Although Compound X did not show an anti-bacterial effect, the fact that isoniazid reduced bacterial load contributed reliable data to the project.